Cargando…
Mobile App to Enhance Patient Activation and Patient-Provider Communication in Major Depressive Disorder Management: Collaborative, Randomized Controlled Pilot Study
BACKGROUND: Enhanced patient-provider engagement can improve patient health outcomes in chronic conditions, including major depressive disorder (MDD). OBJECTIVE: We evaluated the impact of a digitally enabled care mobile app, Pathway, designed to improve MDD patient-provider engagement. Patients use...
Autores principales: | McCue, Maggie, Blair, Christopher, Fehnert, Ben, King, James, Cormack, Francesca, Sarkey, Sara, Eramo, Anna, Kabir, Christopher, Khatib, Rasha, Kemp, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9650572/ https://www.ncbi.nlm.nih.gov/pubmed/36301599 http://dx.doi.org/10.2196/34923 |
Ejemplares similares
-
Design and Implementation of a Digitally Enabled Care Pathway to Improve Management of Depression in a Large Health Care System: Protocol for the Implementation of a Patient Care Platform
por: Khatib, Rasha, et al.
Publicado: (2023) -
User-Centered Design of a Digitally Enabled Care Pathway in a Large Health System: Qualitative Interview Study
por: McCue, Maggie, et al.
Publicado: (2023) -
Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
por: McCue, Maggie, et al.
Publicado: (2021) -
Correction to: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
por: McCue, Maggie, et al.
Publicado: (2022) -
Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study
por: McCue, Maggie, et al.
Publicado: (2022)